Drugs / LAIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06841913 | Sep 2025 → Dec 2028 expected | influenza | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06841913 ↗ |
| Modality | Vaccine | “LAIV nasal vaccine is chosen as a model viral infection” NCT06841913 ↗ |
| Route | Intranasal | “LAIV nasal vaccine” NCT06841913 ↗ |